People In Brief
This article was originally published in The Gray Sheet
Executive Summary
Cordis appointments: Johnson & Johnson interventional cardiology division has filled three VP-level positions, the firm said Oct. 13. Carl St. Bernard joins Cordis as VP of U.S. sales and marketing. He was previously general manager of the magnetic resonance imaging unit at GE Healthcare. Paul Chang has moved from J&J's pharmaceutical R&D team to become Cordis' VP-worldwide clinical research and operations. Finally, Ryan Saadi, formerly of Genzyme, is tapped to fill the health economics and reimbursement VP role. A Cordis spokesperson would not comment on progress in filling two other high-level positions for worldwide president and chief medical officer previously reported to be vacant (1"The Gray Sheet" June 23, 2008, p. 8)
You may also be interested in...
People In Brief
AGA Medical CEO and IPO: Structural heart defect devices firm names a new CEO June 20 and on the same day files with the U.S. Securities and Exchange Commission for an initial public stock offering to raise up to $200 million. Chief Operating Officer John Barr is appointed president and CEO to replace Frank Gougeon, who co-founded the company with Kurt Amplatz in 1995. AGA says that Gougeon has decided to transition from day-to-day company oversight to an expanded role in long-term strategic planning. He will remain a member of the company's board and will chair a new corporate development committee
Endocare To Shed Non-Core Assets, Focus On Cryocare Indications
Endocare is divesting "certain non-core" assets in order to concentrate resources on expanding adoption of its Cryocare prostate cancer platform and pursuit of additional applications
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.